Acrivon Therapeutics | ApexOnco - Clinical Trials news and analysis

x

“The team is super responsive to my inquiries and suggestions”

Chief Business Officer

US public biotech company

Click here for more information

Data insights

13 November 2024

Regeneron keeps up its co-stimulatory crusade

The company’s CD38 x CD28 MAb is among recent clinical trial entrants.

Deals

7 March 2024

Boundless enthusiasm for CHK1

Conferences Trial results

16 October 2023

Triple meeting 2023 – no monotherapy activity for Repare

Subscribe to Acrivon Therapeutics